Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MEMBRANEBLUE vs CARDRASE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Methylene blue (Membraneblue) is a selective inhibitor of guanylyl cyclase, thereby reducing cyclic guanosine monophosphate (c GMP) levels. It also acts as an electron carrier in the reduction of methemoglobin to hemoglobin.
CARDRASE is a nonsteroidal anti-inflammatory drug that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), thereby reducing the synthesis of prostaglandins involved in inflammation, pain, and fever.
Treatment of acquired methemoglobinemia,Diagnostic staining (e.g., parathyroid glands, lymphatic mapping),Off-label: Refractory vasoplegic shock, prevention of ifosfamide neurotoxicity
Rheumatoid arthritis,Osteoarthritis,Ankylosing spondylitis,Acute gouty arthritis,Primary dysmenorrhea
2 mg/kg intravenously once, administered over 30 minutes; may repeat once if clinically indicated after 30 minutes.
Adult: 100 mg orally twice daily.
Terminal elimination half-life 2.5-3.5 hours in adults; prolonged in hepatic or renal impairment (up to 6-8 hours).
Terminal elimination half-life is 12-15 hours in adults with normal renal function; prolonged to 24-40 hours in severe renal impairment (Cr Cl <30 m L/min).
Reduced by NADPH-dependent methemoglobin reductase to leukomethylene blue; excreted in urine and bile.
Hepatic metabolism primarily via CYP2C9, with minor contributions from CYP3A4 and CYP2C8. Metabolites are inactive and excreted renally.
Renal: approximately 60-70% unchanged; biliary/fecal: 20-30% as conjugated metabolites; minor pulmonary excretion.
Primarily renal excretion of unchanged drug (60-70%) and glucuronide conjugate (10-20%); biliary/fecal elimination accounts for 10-15%.
Approximately 85-90% bound to albumin and alpha-1-acid glycoprotein.
98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
0.35-0.45 L/kg, indicating primarily extracellular distribution.
0.2-0.3 L/kg, indicating limited distribution into tissues, consistent with high plasma protein binding.
Intravenous: 100% (only route); oral bioavailability negligible (<1%) due to extensive first-pass metabolism.
Oral bioavailability is 80-90% with modest first-pass metabolism; intravenous administration yields 100% bioavailability.
No specific dose adjustment recommended; use caution in severe renal impairment (e GFR <30 m L/min/1.73 m²) due to limited data.
GFR ≥60 m L/min: No adjustment. GFR 30-59 m L/min: 100 mg once daily. GFR 15-29 m L/min: 50 mg once daily. GFR <15 m L/min: Not recommended.
No specific dose adjustment recommended; use with caution in severe hepatic impairment (Child-Pugh Class C) due to potential for altered metabolism.
Child-Pugh A: No adjustment. Child-Pugh B: 50 mg once daily. Child-Pugh C: Not recommended.
2 mg/kg intravenously once, not to exceed 100 mg total dose; repeat dosing not typically recommended.
Children ≥1 year: 2 mg/kg orally twice daily, up to a maximum of 100 mg/dose.
No specific dose adjustment required; monitor for renal function and fluid overload due to age-related physiological changes.
Initial dose of 50 mg once daily; may increase to 100 mg once daily based on tolerability.
Serotonin syndrome with concurrent serotonergic drugs (especially SSRIs, SNRIs, MAOIs); discontinue serotonergic agents prior to use; do not use in patients taking serotonergic drugs.
Increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. Risk increases with duration of use and in patients with cardiovascular risk factors. Contraindicated for treatment of perioperative pain in coronary artery bypass graft surgery.
Risk of serotonin syndrome when used with serotonergic agents; may cause severe hemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency; may cause interferences with pulse oximetry readings; monitor methemoglobin levels; may cause fetal harm.
Cardiovascular risk, gastrointestinal bleeding, renal toxicity, hypertension, fluid retention, anaphylactoid reactions, serious skin reactions, hematologic toxicity, hepatic impairment, asthma exacerbation, and use in pregnancy (avoid in later stages).
Known hypersensitivity to methylene blue; concurrent use with serotonergic drugs (SSRIs, SNRIs, MAOIs); severe G6PD deficiency.
Hypersensitivity to CARDRASE or any NSAID; history of asthma, urticaria, or allergic-type reactions after aspirin or NSAIDs; perioperative pain in CABG surgery; advanced renal disease; severe hepatic impairment; active peptic ulcer or GI bleeding; third trimester of pregnancy; patients with known sulfonamide allergy (if applicable).
No known food interactions. Avoid alcohol consumption for 24 hours post-administration due to potential increased sedative effects.
Avoid high-sodium foods to reduce fluid retention. Limit intake of potassium-rich foods if hyperkalemia is a risk. Grapefruit juice may increase drug levels; avoid concurrent use.
Current evidence indicates no increased risk of major congenital malformations with prenatal exposure. No known fetal risks during any trimester. However, human data are limited.
First trimester: Potential for increased risk of major malformations based on animal studies; human data insufficient. Second trimester: No specific fetal risks identified. Third trimester: Risk of neonatal hypoglycemia, hypotonia, and respiratory depression with maternal use near term.
Breastfeeding safety not established. M/P ratio unknown. Use caution during lactation due to potential for excretion.
Limited data; drug is excreted in breast milk. M/P ratio unknown. Avoid breastfeeding during therapy due to potential adverse effects in the infant.
No dose adjustment required based on pharmacokinetic changes during pregnancy.
Increased renal clearance during pregnancy may require 20-30% dose escalation in second and third trimesters. Monitor therapeutic drug levels to maintain efficacy. Consider dose reduction postpartum.
MEMBRANEBLUE (methylene blue) 1% solution is used intravenously for methemoglobinemia and as an optical imaging agent. Monitor for serotonergic toxicity if combined with SSRIs/SNRIs due to MAO inhibition. Do not exceed 7 mg/kg total dose to avoid severe adverse effects. Use with caution in G6PD deficiency due to risk of hemolytic anemia.
CARDRASE (carbonic anhydrase inhibitor) may cause metabolic acidosis; monitor serum bicarbonate. Contraindicated in cirrhosis due to risk of hepatic encephalopathy. Can cause hypokalemia; check electrolytes. Adjust dose in renal impairment (Cr Cl <30 m L/min).
This medication may cause your urine, stool, or skin to turn blue-green, which is harmless and temporary.,Report any severe headache, chest pain, or difficulty breathing immediately.,Avoid taking medications for depression, anxiety, or migraine (SSRIs, SNRIs, MAOIs) within 24 hours of receiving MEMBRANEBLUE unless directed by your doctor.,If you have a history of glucose-6-phosphate dehydrogenase (G6PD) deficiency, inform your healthcare provider before treatment.
Take with food to reduce gastrointestinal upset.,Drink plenty of fluids to prevent kidney stones.,Avoid prolonged sun exposure; use sunscreen as photosensitivity may occur.,Report unexplained bruising or bleeding, as it may indicate thrombocytopenia.,Do not drive or operate machinery until you know how this medication affects you, as dizziness or drowsiness can occur.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MEMBRANEBLUE vs CARDRASE, answered by our medical review team.
MEMBRANEBLUE is a Ophthalmic Dye that works by Methylene blue (Membraneblue) is a selective inhibitor of guanylyl cyclase, thereby reducing cyclic guanosine monophosphate (c GMP) levels. It also acts as an electron carrier in the reduction of methemoglobin to hemoglobin.. CARDRASE is a Antiarrhythmic Agent that works by CARDRASE is a nonsteroidal anti-inflammatory drug that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), thereby reducing the synthesis of prostaglandins involved in inflammation, pain, and fever.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MEMBRANEBLUE and CARDRASE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MEMBRANEBLUE is: 2 mg/kg intravenously once, administered over 30 minutes; may repeat once if clinically indicated after 30 minutes.. The standard adult dose of CARDRASE is: Adult: 100 mg orally twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MEMBRANEBLUE and CARDRASE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MEMBRANEBLUE is classified as Category C. Current evidence indicates no increased risk of major congenital malformations with prenatal exposure. No known fetal risks during any trimester. However, human data are limited.. CARDRASE is classified as Category C. First trimester: Potential for increased risk of major malformations based on animal studies; human data insufficient. Second trimester: No specific fetal risks identified. Third t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.